去唾液酸糖蛋白受体介导的肝靶向研究进展

Progress on ASGPR-Mediated Hepatic Targeting

关键词:  唾液酸糖蛋白受体  肝癌  乙型肝炎

Key words:  asialoglycoprotein receptor  liver cancer  HBV

摘要:

目的 介绍去唾液酸糖蛋白受体(asialoglycoprotein receptor，ASGPR)介导的药物和基因肝靶向作用和机制，及其在治疗肝癌和乙型肝炎实验研究方面的最新进展。方法 查阅和选取针对性强、相关度高的文献，总结和归纳ASGPR介导的药物和基因肝靶向用于治疗肝癌和乙型肝炎的最新研究进展。结果 ASGPR是肝细胞的一种重要且高效的内吞受体，可用于介导药物和基因的肝靶向递送。结论 ASGPR介导的药物和基因肝靶向有望成为肝癌和乙型肝炎治疗的有效手段。

Abstract:

OBJECTIVE To introduce asialoglycoprotein receptor(ASGPR) and the latest experimental progress on ASGPR-mediated drug/gene hepatic targeting for the treatment of liver cancer and hepatitis B virus(HBV). METHODS Based on the relevant literatures, new achievements in studies of ASGPR-mediated drug/gene liver targeting for the treatment of liver cancer and HBV are reviewed. RESULTS ASGPR is predominantly expressed on the sinusoidal surface of mammalian hepatocytes and is involved in many physiological functions, which could be used for drug/gene liver-targeting delivery. CONCLUSION ASGPR-mediated drug/gene hepatic targeting against liver cancer and HBV is expected to be an effective means of treatment.